Arming “old guards” with “new dual-targeting weapons”

Lum, Lawrence G.; Tushir-Singh, Jogender

doi:10.1016/j.ccell.2021.04.010

Cited by 3 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…300,454,455 As a result, TCRm antibodies-based strategy could be used to target neoantigens originating from mutations in both oncogenes and TSGs that are challenging to eradicate using traditional methods, enabling the development of more targeted anti-cancer therapies. 452,[456][457][458][459] Given TCR mimic antibodies have a much better affinity to peptide-HLA molecules than natural TCRs. To prevent cross-reactivity or binding of the HLA component unrelated to the given peptide, TCR mimic antibodies must be properly screened.…”

Section: Genetically Engineered Anti-tumor Immune Cells Immune Cells ...mentioning

confidence: 99%

Neoantigens: promising targets for cancer therapy

Xie

Shen

Gao

et al. 2023

Sig Transduct Target Ther

235

150

View full text Add to dashboard Cite

Recent advances in neoantigen research have accelerated the development and regulatory approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and antibody-based therapies, especially for solid tumors. Neoantigens are newly formed antigens generated by tumor cells as a result of various tumor-specific alterations, such as genomic mutation, dysregulated RNA splicing, disordered post-translational modification, and integrated viral open reading frames. Neoantigens are recognized as non-self and trigger an immune response that is not subject to central and peripheral tolerance. The quick identification and prediction of tumor-specific neoantigens have been made possible by the advanced development of next-generation sequencing and bioinformatic technologies. Compared to tumor-associated antigens, the highly immunogenic and tumor-specific neoantigens provide emerging targets for personalized cancer immunotherapies, and serve as prospective predictors for tumor survival prognosis and immune checkpoint blockade responses. The development of cancer therapies will be aided by understanding the mechanism underlying neoantigen-induced anti-tumor immune response and by streamlining the process of neoantigen-based immunotherapies. This review provides an overview on the identification and characterization of neoantigens and outlines the clinical applications of prospective immunotherapeutic strategies based on neoantigens. We also explore their current status, inherent challenges, and clinical translation potential.

show abstract

Section: Genetically Engineered Anti-tumor Immune Cells Immune Cells ...mentioning

confidence: 99%

Neoantigens: promising targets for cancer therapy

Xie

Shen

Gao

et al. 2023

Sig Transduct Target Ther

235

150

View full text Add to dashboard Cite

show abstract

“…Although the prevalent view used to be that tumor suppressors (which include metastasis suppressors) are un-targetable [141], there is now a paradigm shift since the recent report of Hsiue et al [142] on p53 mutant peptide-targeted immunotherapy, albeit an antibody-based therapeutic that targets the most commonly mutated tumor suppressor gene.…”

Section: Challenges and Future Directionsmentioning

confidence: 99%

Targeting CD82/KAI1 for Precision Therapeutics in Surmounting Metastatic Potential in Breast Cancer

Viera

Yip

Shen

et al. 2021

Cancers

View full text Add to dashboard Cite

Metastasis is the main cause of mortality in breast cancer patients. There is an unmet need to develop therapies that can impede metastatic spread. Precision oncology has shown great promise for the treatment of cancers, as the therapeutic approach is tailored to a specific group of patients who are likely to benefit from the treatment, rather than the traditional approach of “one size fits all”. CD82, also known as KAI1, a glycoprotein belonging to the tetraspanin family and an established metastasis suppressor, could potentially be exploited to hinder metastases in breast cancer. This review explores the prospect of targeting CD82 as an innovative therapeutic approach in precision medicine for breast cancer patients, with the goal of preventing cancer progression and metastasis. Such an approach would entail the selection of a subset of breast cancer patients with low levels of CD82, and instituting an appropriate treatment scheme tailored towards restoring the levels of CD82 in this group of patients. Proposed precision treatment regimens include current modalities of treating breast cancer, in combination with either clinically approved drugs that could restore the levels of CD82, CD82 peptide mimics or non-coding RNA-based therapeutics.

show abstract

“…9 ). Considering that externally provided antibody-based targeting of intracellular proteins (such as those residing in the cytosol, ER, or TGN network) is nearly impossible ( 46 ), FuG1 strategy-mediated targeting of furin likely operates outside TGN. Nonetheless, the regulatory role of furin in the endosomal network and cell surface is well established ( 28 ).…”

Section: Discussionmentioning

confidence: 99%